AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 956103 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg ascorbic acid
Number of subjects: 60
Study 956103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31108557 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidirectional barbed sutures (BBSs)
Number of subjects: 85
Study 31108557 — intervention group
Group type: COMPARATOR
Intervention: Traditional closure with Vicryl (V-group)
Number of subjects: 85
Study 30532984 — intervention group
Group type: COMPARATOR
Intervention: 40 Gy whole-breast radiotherapy (control)
Number of subjects: 1265
Study 30532984 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 Gy whole-breast and 40 Gy partial-breast radiotherapy (reduced-dose)
Number of subjects: 1265
Study 30532984 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Gy partial-breast radiotherapy only (partial-breast)
Number of subjects: 1265
Study 30532984 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 1265
Study 28398471 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher amounts of joule energy and treatment planes
Number of subjects: 0
Study 28398471 — intervention group
Group type: COMPARATOR
Intervention: Control treatment with lower joule energy and treatment planes
Number of subjects: 0
Study 25757188 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol Easyhaler
Number of subjects: 4
Study 23933006 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-tar cigarette
Number of subjects: 16
Study 23933006 — intervention group
Group type: EXPERIMENTAL
Intervention: High-tar cigarette
Number of subjects: 16
Study 23933006 — intervention group
Group type: COMPARATOR
Intervention: Both low-tar and high-tar cigarettes
Number of subjects: 16
Study 20888091 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron (100 mg/day as ferrous sulphate) and folic acid (500 μg/day) supplementation
Number of subjects: 117
Study 20888091 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 mg cane sugar)
Number of subjects: 117
Study 19780802 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS
Number of subjects: 36
Study 19780802 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 Hz rTMS
Number of subjects: 36
Study 19780802 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 36
Study 16413752 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose creatine supplementation (20 g/d for 1 week)
Number of subjects: 0
Study 16413752 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose creatine supplementation (5 g/d for 20 weeks)
Number of subjects: 0
Study 16413752 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 12562873 — intervention group
Group type: EXPERIMENTAL
Intervention: FHBL subjects
Number of subjects: 21
Study 12562873 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 21
Study 11142453 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person intercessory prayer
Number of subjects: 40
Study 11142453 — intervention group
Group type: COMPARATOR
Intervention: Supplemental, distant intercessory prayer
Number of subjects: 40
Study 8967707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxacillin alone (2 g intravenously every 4 hours for 14 days)
Number of subjects: 90
Study 8967707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxacillin plus gentamicin (1 mg/kg intravenously every 8 hours for 7 days)
Number of subjects: 90
Study 8967707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxacillin alone
Number of subjects: 90
Study 8967707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxacillin plus gentamicin
Number of subjects: 90
Study 7903135 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 20 micrograms/kg
Number of subjects: 60
Study 7903135 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 50 micrograms/kg
Number of subjects: 60
Study 7903135 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 100 micrograms/kg
Number of subjects: 60
Study 7903135 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 200 micrograms/kg
Number of subjects: 60
Study 7903135 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 60
Study 7903135 — intervention group
Group type: EXPERIMENTAL
Intervention: All dosages of ivermectin
Number of subjects: 60
Study 3898930 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (single intramuscular dose)
Number of subjects: 52
Study 3898930 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (standard five-day regimen)
Number of subjects: 52
Study 3898930 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 52
Study 3898930 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 52
Study 29949889 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight Collagen peptide (LMWCP) 1000 mg once daily for 12 weeks
Number of subjects: 64
Study 29949889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 27923369 — intervention group
Group type: EXPERIMENTAL
Intervention: Shu-Gan-Jian-Pi Decoction combined with prednisone and azathioprine
Number of subjects: 132
Study 27923369 — intervention group
Group type: COMPARATOR
Intervention: Prednisone and azathioprine
Number of subjects: 132
Study 24119887 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced postoperative recovery pathways (Group 2)
Number of subjects: 47
Study 24119887 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative care (Group 1)
Number of subjects: 47
Study 22694755 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-free (SF) immunosuppression
Number of subjects: 130
Study 22694755 — intervention group
Group type: COMPARATOR
Intervention: Steroid-based (SB) immunosuppression
Number of subjects: 130
Study 22694755 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-free (SF) immunosuppression (subgroup under 5 years)
Number of subjects: 130
Study 22694755 — intervention group
Group type: COMPARATOR
Intervention: Steroid-based (SB) immunosuppression (subgroup under 5 years)
Number of subjects: 130
Study 19962115 — intervention group
Group type: EXPERIMENTAL
Intervention: Group phone-based treatment
Number of subjects: 34
Study 19962115 — intervention group
Group type: COMPARATOR
Intervention: Individual phone-based treatment
Number of subjects: 34
Study 18555578 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebaudioside A
Number of subjects: 0
Study 18555578 — intervention group
Group type: EXPERIMENTAL
Intervention: Stevioside
Number of subjects: 0
Study 15767846 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 200 mg
Number of subjects: 22
Study 15767846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 12068794 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 469
Study 12068794 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant radiotherapy)
Number of subjects: 469
Study 10467921 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic suggestions to decrease pain affect (Experiment one)
Number of subjects: 0
Study 10467921 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic suggestions to increase and decrease pain affect (Experiment two)
Number of subjects: 0
Study 10467921 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic suggestions to modulate sensory aspect of pain (Experiment three)
Number of subjects: 0
Study 8546501 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal HIV infection
Number of subjects: 476
Study 8546501 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug use during pregnancy
Number of subjects: 476
Study 8546501 — intervention group
Group type: COMPARATOR
Intervention: Community controls
Number of subjects: 476
Study 2141931 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiocolchicoside
Number of subjects: 98
Study 2141931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 231914 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg tubocurarine
Number of subjects: 76
Study 231914 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.04 mg/kg pancuronium bromide
Number of subjects: 76
Study 231914 — intervention group
Group type: COMPARATOR
Intervention: Control (sodium nitroprusside with tubocurarine)
Number of subjects: 76
Study 231914 — intervention group
Group type: COMPARATOR
Intervention: Control (sodium nitroprusside with pancuronium bromide)
Number of subjects: 76
Study 31448737 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 0
Study 31448737 — intervention group
Group type: COMPARATOR
Intervention: Awake-regional anaesthesia
Number of subjects: 0
Study 29241379 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoro‐edenite (FE) exposure
Number of subjects: 120
Study 29241379 — intervention group
Group type: COMPARATOR
Intervention: Non-exposed subjects
Number of subjects: 120
Study 26873050 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronome-guided CPR at 120 compressions/min after training at 100 compressions/min
Number of subjects: 37
Study 26873050 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronome-guided CPR at 120 compressions/min after training at 120 compressions/min
Number of subjects: 37
Study 26873050 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronome-guided CPR at 120 compressions/min after training at 140 compressions/min
Number of subjects: 37
Study 24605921 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 96
Study 24605921 — intervention group
Group type: COMPARATOR
Intervention: Well-rested condition
Number of subjects: 96
Study 22679722 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medical facial mask (twice a week for 4 weeks)
Number of subjects: 233
Study 22679722 — intervention group
Group type: COMPARATOR
Intervention: 5% benzoyl peroxide gel (once in the evening for 4 weeks)
Number of subjects: 233
Study 22679722 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medical facial mask
Number of subjects: 233
Study 22679722 — intervention group
Group type: COMPARATOR
Intervention: 5% benzoyl peroxide gel
Number of subjects: 233
Study 20885412 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum twice a day after breakfast and lunch (G1)
Number of subjects: 82
Study 20885412 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum plus chlorhexidine varnish (G2)
Number of subjects: 82
Study 20885412 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish (G3)
Number of subjects: 82
Study 20885412 — intervention group
Group type: COMPARATOR
Intervention: Fluoride gel application (G4)
Number of subjects: 82
Study 18163038 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS treatment for major depressive disorder (MDD)
Number of subjects: 2
Study 18163038 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS as a maintenance intervention for MDD (approximately 2 rTMS sessions/week)
Number of subjects: 2
Study 15608043 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.25%
Number of subjects: 99
Study 15608043 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.25%
Number of subjects: 99
Study 15608043 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine 0.25%
Number of subjects: 99
Study 11883386 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 11245
Study 11883386 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac or Ketoprofen
Number of subjects: 11245
Study 10712710 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental induction with sevoflurane (2,4,6,7%) in 100% O2 (group IC-O2)
Number of subjects: 65
Study 10712710 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction with high concentration of sevoflurane in 100% O2 (group HC-O2)
Number of subjects: 65
Study 10712710 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction with high concentration of sevoflurane in a mixture of O2:N2O (50:50) (group HC-N2O)
Number of subjects: 65
Study 10712710 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 65
Study 7488983 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic thermography
Number of subjects: 0
Study 2021297 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (200 to 800 mg/d)
Number of subjects: 40
Study 2021297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6122846 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshly prepared penicillin-G solution administered as a bolus
Number of subjects: 0
Study 6122846 — intervention group
Group type: COMPARATOR
Intervention: Penicillin-G solution stored for a few hours
Number of subjects: 0
Study 31907027 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp acupuncture combined with conventional rehabilitation treatment
Number of subjects: 100
Study 31907027 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation treatment alone
Number of subjects: 100
Study 30232416 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian phase (biological evening)
Number of subjects: 0
Study 30232416 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian misalignment (12-h behavioral cycle inversion)
Number of subjects: 0
Study 30232416 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian misalignment
Number of subjects: 0
Study 28287803 — intervention group
Group type: EXPERIMENTAL
Intervention: Benefit-finding intervention
Number of subjects: 96
Study 28287803 — intervention group
Group type: COMPARATOR
Intervention: SIM-PE (simplified psychoeducation)
Number of subjects: 96
Study 28287803 — intervention group
Group type: COMPARATOR
Intervention: STD-PE (standard psychoeducation)
Number of subjects: 96
Study 25201508 — intervention group
Group type: COMPARATOR
Intervention: Belief that quitting will benefit their children
Number of subjects: 981
Study 25201508 — intervention group
Group type: COMPARATOR
Intervention: Education level (more than high school)
Number of subjects: 981
Study 25201508 — intervention group
Group type: COMPARATOR
Intervention: Having children under age 3 years
Number of subjects: 981
Study 25201508 — intervention group
Group type: COMPARATOR
Intervention: Prior quit attempt
Number of subjects: 981
Study 22857752 — intervention group
Group type: EXPERIMENTAL
Intervention: HAL-induced fluorescence
Number of subjects: 102
Study 22857752 — intervention group
Group type: COMPARATOR
Intervention: White light
Number of subjects: 102
Study 20500899 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernonia cinerea (VC) supplement
Number of subjects: 0
Study 20500899 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with VC supplement
Number of subjects: 0
Study 20500899 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0
Study 20500899 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 17650659 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture of acupoints of the Stomach Meridian (bilateral Liangmen (ST 21), Huaroumen (ST 24), Tianshu (ST 25), Wailing (ST 26))
Number of subjects: 51
Study 17650659 — intervention group
Group type: COMPARATOR
Intervention: Control group acupuncture of Back‐Shu and Front‐Mu points (bilateral Weishu (BL 21), Dachangshu (BL 25), Xiaochangshu (BL 27), Hegu (LI 4) with electrical stimulation)
Number of subjects: 51
Study 17650659 — intervention group
Group type: COMPARATOR
Intervention: Treatment group vs control group
Number of subjects: 51
Study 16230048 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label eszopiclone (3mg)
Number of subjects: 360
Study 16230048 — intervention group
Group type: COMPARATOR
Intervention: Double-blind placebo (initially) then switched to open-label eszopiclone
Number of subjects: 360
Study 11911518 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based traditional exercise group (TEG)
Number of subjects: 47
Study 11911518 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based functional exercise group (FEG)
Number of subjects: 47
Study 11911518 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 47
Study 10423054 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 25
Study 10423054 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 25
Study 7750528 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette‐Guerin (BCG) immunotherapy
Number of subjects: 0
Study 7750528 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance BCG using three weekly treatments at 6-month intervals
Number of subjects: 0
Study 7750528 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 6-week course of BCG
Number of subjects: 0
Study 2246098 — intervention group
Group type: EXPERIMENTAL
Intervention: Maharishi Amrit Kalash (MAK) tablets, twice daily for six weeks
Number of subjects: 48
Study 2246098 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice daily for six weeks
Number of subjects: 48
Study 7044881 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation (0.5-1s pulses, 55-80 W power)
Number of subjects: 152
Study 7044881 — intervention group
Group type: COMPARATOR
Intervention: Laser photocoagulation
Number of subjects: 152
Study 7044881 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 152
Study 7044881 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 152
Study 31492176 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital diabetes diary app
Number of subjects: 24
Study 31492176 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from health-care personnel
Number of subjects: 24
Study 31492176 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine use of the app
Number of subjects: 24
Study 31492176 — intervention group
Group type: EXPERIMENTAL
Intervention: Utility of the app
Number of subjects: 24
Study 31492176 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital and clinical distress
Number of subjects: 24
Study 27791311 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical minoxidil 5% solution
Number of subjects: 90
Study 27791311 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelets rich plasma injections
Number of subjects: 90
Study 27791311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 26491273 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Number of subjects: 0
Study 26491273 — intervention group
Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 0
Study 23392463 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8 T-cell activation measured by CD38/HLA-DR expression
Number of subjects: 0
Study 23392463 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8 T-cell activation during viral suppression <50 copies per milliliter
Number of subjects: 0
Study 24688618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (education, pharmacotherapy monitoring, detecting and solving drug related problems)
Number of subjects: 84
Study 24688618 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmaceutical services (dispensing medicines with or without counseling)
Number of subjects: 84
Study 24688618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care
Number of subjects: 84
Study 19363097 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated health question asked before chronic conditions in Spanish interviews
Number of subjects: 0
Study 19363097 — intervention group
Group type: COMPARATOR
Intervention: Self-rated health question asked after chronic conditions in Spanish interviews
Number of subjects: 0
Study 19363097 — intervention group
Group type: COMPARATOR
Intervention: Self-rated health question asked in English interviews
Number of subjects: 0
Study 17534745 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 microg b.i.d.
Number of subjects: 45
Study 17534745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 16886928 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole 0.142 mg/kg per min administered intravenously
Number of subjects: 20
Study 15363419 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid injections (ESI)
Number of subjects: 232
Study 15363419 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradiscal steroid injections (ISI)
Number of subjects: 232
Study 15363419 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid injections (ESI) in patients with inflammatory end‐plate changes
Number of subjects: 232
Study 15363419 — intervention group
Group type: EXPERIMENTAL
Intervention: Discography with or without intradiscal steroid
Number of subjects: 232
Study 11112935 — intervention group
Group type: EXPERIMENTAL
Intervention: Valpromide
Number of subjects: 15
Study 8683189 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition 1: 12 presentations of a 2‐s visual stimulus
Number of subjects: 50
Study 8683189 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition 2: 12 short stimuli presentations accompanied by another event
Number of subjects: 50
Study 8683189 — intervention group
Group type: COMPARATOR
Intervention: Condition 3: Infant-control procedure with repeated presentation of the same stimulus
Number of subjects: 50
Study 1327657 — intervention group
Group type: EXPERIMENTAL
Intervention: 5g of creatine monohydrate, four or six times a day for 2 or more days
Number of subjects: 17
Study 1327657 — intervention group
Group type: EXPERIMENTAL
Intervention: 5g of creatine monohydrate every 2 hours
Number of subjects: 17
Study 1327657 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 x 5g of creatine monohydrate/day
Number of subjects: 17
Study 1327657 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 17
Study 3874037 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (30 or 60 mg) with ethanol (45 ml absolute alcohol per 70 kg body weight)
Number of subjects: 0
Study 3874037 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (30 or 60 mg)
Number of subjects: 0
Study 31679186 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine (F)/TAF
Number of subjects: 31
Study 31679186 — intervention group
Group type: COMPARATOR
Intervention: Control (current antiretroviral therapy)
Number of subjects: 31
Study 31077827 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily (induction)
Number of subjects: 1157